Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension
Primary Purpose
Pulmonary Arterial Hypertension (PAH)
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Magnetic Resonance Imaging (MRI) with exercise
Sponsored by
About this trial
This is an interventional diagnostic trial for Pulmonary Arterial Hypertension (PAH)
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of pulmonary arterial hypertension or a subtype
- Referred for right heart catheterization
- Age between 18 and 80 years
- New York Heart Association (NYHA) functional class I, II, or III
Exclusion Criteria:
- Recent syncope (within 1 year)
- Severe skeletal or muscle abnormalities prohibiting exercise
- Mixed etiology pulmonary arterial hypertension
Severe lung disease
- Test results indicating severe obstruction
- Total lung capacity < 60%
- Pregnancy or breastfeeding
- NYHA class IV patient
- Contraindications to magnetic resonance imaging
- Kidney dysfunction as determined by an estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73m2
- Contraindication to gadolinium
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Patient
Arm Description
A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
Outcomes
Primary Outcome Measures
The primary outcome is to comprehensively quantify right ventricular and pulmonary vascular function at rest and with exercise using magnetic resonance imaging.
The hypotheses will be tested by comprehensively quantifying ventricular and vascular function in subjects with idiopathic pulmonary arterial hypertension, systemic sclerosis pulmonary arterial hypertension, and chronic thromboembolic pulmonary hypertension, using investigational magnetic resonance angiography techniques.
Secondary Outcome Measures
Full Information
NCT ID
NCT03523910
First Posted
February 26, 2018
Last Updated
May 1, 2018
Sponsor
University of Wisconsin, Madison
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT03523910
Brief Title
Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension
Official Title
Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
April 25, 2012 (Actual)
Primary Completion Date
February 13, 2017 (Actual)
Study Completion Date
February 13, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goals of this study were two-fold. First, the attempt to quantify the relationships between pulmonary arterial stiffness, right ventricular function and the efficiency of ventricular-vascular interactions in patients with pulmonary arterial hypertension (PAH). Second, the attempt to quantify the effects of exercise on pulmonary arterial stiffness, pulmonary vascular resistance, right ventricular function and the efficiency of ventricular-vascular interactions in patients with PAH.
Detailed Description
The goals of this study are to quantify right ventricular-pulmonary vascular interactions in different types of PAH, to determine the temporal changes in these interactions with PAH progression and to quantify the effects of exercise on right ventricular function. The inclusion of the subpopulation of PAH patients with systemic sclerosis (SSc) was a result of the anticipation that this group has worse arterial stiffening than other groups, and consequently more inefficient right ventricular-pulmonary vascular interactions, which account for their worse prognosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Arterial Hypertension (PAH)
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single center, open label, single-arm
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Patient
Arm Type
Experimental
Arm Description
A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
Intervention Type
Device
Intervention Name(s)
Magnetic Resonance Imaging (MRI) with exercise
Other Intervention Name(s)
MRI
Intervention Description
MRI scan with a novel exercise device.
Primary Outcome Measure Information:
Title
The primary outcome is to comprehensively quantify right ventricular and pulmonary vascular function at rest and with exercise using magnetic resonance imaging.
Description
The hypotheses will be tested by comprehensively quantifying ventricular and vascular function in subjects with idiopathic pulmonary arterial hypertension, systemic sclerosis pulmonary arterial hypertension, and chronic thromboembolic pulmonary hypertension, using investigational magnetic resonance angiography techniques.
Time Frame
Up to 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of pulmonary arterial hypertension or a subtype
Referred for right heart catheterization
Age between 18 and 80 years
New York Heart Association (NYHA) functional class I, II, or III
Exclusion Criteria:
Recent syncope (within 1 year)
Severe skeletal or muscle abnormalities prohibiting exercise
Mixed etiology pulmonary arterial hypertension
Severe lung disease
Test results indicating severe obstruction
Total lung capacity < 60%
Pregnancy or breastfeeding
NYHA class IV patient
Contraindications to magnetic resonance imaging
Kidney dysfunction as determined by an estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73m2
Contraindication to gadolinium
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher Francois, MD
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
30577768
Citation
Macdonald JA, Franҫois CJ, Forouzan O, Chesler NC, Wieben O. MRI assessment of aortic flow in patients with pulmonary arterial hypertension in response to exercise. BMC Med Imaging. 2018 Dec 22;18(1):55. doi: 10.1186/s12880-018-0298-9.
Results Reference
derived
Learn more about this trial
Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension
We'll reach out to this number within 24 hrs